The sixth annual Productive Innovation Index released by IDEA Pharma, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of first place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga(R) (prostate cancer), Imbruvica(R) (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi(R)/Simponi Aria(R) (rheumatoid arthritis), Stelara(R) (psoriasis and psoriatic arthritis), Invega Sustenna(R) and Invega Trinza(R) (schizophrenia).
Takeda was a major mover on the Index this year, rising fourteen places to take second place.
The principal driver for this change is strong sales growth across the US and emerging markets, having benefitted from a significant number of new drugs in the last twelve to 18 months in the form of Entyvio(R) (ulcerative colitis and Crohn’s disease), Takecab(R) (for acid-related GI disorders), Adcetris(R) (lymphoma) and Brintellix(R) (major depressive disorder).
Moving up fifteen places to third is Denmark’s Novo Nordisk. The company continues to occupy leadership positions in front line therapy in type 1 diabetes (T1D) and have a significant share of the type 2 diabetes (T2D) market. This is largely part to strong performances from Victoza(R) (T2D), Levemir(R) (T1 and 2D) and the 2015 launch of Tresiba(R) (for T1 and 2D).
Other high risers inlcude AbbVie moving up twelve places to fifth and Otsuka, rising from 24th last year to assume ninth place.
